Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

(2022) Karen B. Onel et al.   ARTHRITIS CARE & RESEARCH

Efficacy of moderately dosed etoposide in macrophage activation syndrome - hemophagocytic lymphohistiocytosis (MAS-HLH)

(2021) AnnaCarin Horne et al.   JOURNAL OF RHEUMATOLOGY

Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis

(2021) Remco Erkens et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Interfering with Interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)

(2021) Emely L Verweyen et al.   RHEUMATOLOGY

IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS

(2021) Howard Lin et al.   Blood Advances

Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles

(2021) Vivian E Saper et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease : a case report

(2020) Brigitte Bader-Meunier et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China

(2020) Qiongyi Hu et al.   ANNALS OF THE RHEUMATIC DISEASES

Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease

(2020) Satoshi Sato et al.   ANNALS OF THE RHEUMATIC DISEASES

Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy

(2020) Georgia Griffin et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis

(2020) Franco Locatelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019

(2020) Scott W. Canna et al.   Pediatric Rheumatology

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

(2019) Mia Glerup et al.   ARTHRITIS CARE & RESEARCH

Cyclosporine in Resistant Systemic Arthritis - A Cheaper Alternative to Biologics

(2019) Priyankar Pal et al.   INDIAN JOURNAL OF PEDIATRICS

IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome

(2019) Shima Yasin et al.   RHEUMATOLOGY

IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome

(2019) Shima Yasin et al.   RHEUMATOLOGY

Emergent high fatality lung disease in systemic juvenile arthritis

(2019) Vivian E Saper et al.   ANNALS OF THE RHEUMATIC DISEASES

Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease: Characterization and Risk Factors

(2019) Grant S. Schulert et al.   Arthritis & Rheumatology

Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome

(2018) Eric S. Weiss et al.   BLOOD

Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab

(2018) Amélie Leurs et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis

(2018) Victoria L. Arthur et al.   Arthritis & Rheumatology

A comprehensive review on adult onset Still's disease

(2018) Roberto Giacomelli et al.   JOURNAL OF AUTOIMMUNITY

AA amyloidosis –benefits and prospects of IL-6 inhibitors

(2018) Yasuaki Okuda   Modern Rheumatology

Role of plasma exchange, leukocytapheresis, and plasma diafiltration in management of refractory macrophage activation syndrome

(2017) Noriko Kinjo et al.   JOURNAL OF CLINICAL APHERESIS

Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review

(2017) Songkiat Chantarogh et al.   BMC Nephrology

Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis

(2017) Christoph Kessel et al.   Arthritis & Rheumatology

Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications

(2016) Michael J Ombrello et al.   ANNALS OF THE RHEUMATIC DISEASES

The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013

(2016) G. Janow et al.   JOURNAL OF RHEUMATOLOGY

Macrophage activation syndrome in the era of biologic therapy

(2016) Alexei A. Grom et al.   Nature Reviews Rheumatology

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

(2015) Shumpei Yokota et al.   ANNALS OF THE RHEUMATIC DISEASES

Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies

(2015) Grant S. Schulert et al.   Annual Review of Medicine

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis

(2015) V. Boom et al.   Pediatric Rheumatology

Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity

(2015) Nanguneri Nirmala et al.   Pediatric Rheumatology

HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis

(2015) Michael J. Ombrello et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort

(2014) Jaime Guzman et al.   ANNALS OF THE RHEUMATIC DISEASES

2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C

(2014) Sarah Ringold et al.   ARTHRITIS CARE & RESEARCH

Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?

(2014) Peter A. Nigrovic   Arthritis & Rheumatology

Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis

(2014) Norman T. Ilowite et al.   Arthritis & Rheumatology

Using cyclophosphamide in inflammatory rheumatic diseases

(2013) Tobias Brummaier et al.   European Journal of Internal Medicine

Thalidomide for systemic onset juvenile idiopathic arthritis

(2013) K. Sathe et al.   INDIAN PEDIATRICS

Advances from clinical trials in juvenile idiopathic arthritis

(2013) Daniel J. Lovell et al.   Nature Reviews Rheumatology

Interleukin-18, more than a Th1 cytokine

(2013) Daniela Novick et al.   SEMINARS IN IMMUNOLOGY

Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

(2013) Sebastiaan J. Vastert et al.   Arthritis & Rheumatology

Phagocyte-derived S100 proteins in autoinflammation: Putative role in pathogenesis and usefulness as biomarkers

(2012) Christoph Kessel et al.   CLINICAL IMMUNOLOGY

Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles

(2012) Masaki Shimizu et al.   CYTOKINE

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis

(2011) Ekaterina I. Alexeeva et al.   CLINICAL RHEUMATOLOGY

Combination Therapy of Abatacept and Anakinra in Children with Refractory Systemic Juvenile Idiopathic Arthritis: A Retrospective Case Series

(2011) J. L. RECORD et al.   JOURNAL OF RHEUMATOLOGY

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

(2011) Timothy Beukelman et al.   ARTHRITIS CARE & RESEARCH

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

(2010) Peter A. Nigrovic et al.   ARTHRITIS AND RHEUMATISM

Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis

(2010) Claas H Hinze et al.   ARTHRITIS RESEARCH & THERAPY

Tumor Necrosis Factor Inhibitors in the Management of Juvenile Idiopathic Arthritis

(2010) Susan Shenoi et al.   PEDIATRIC DRUGS

Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis

(2009) J Narvaez et al.   ANNALS OF THE RHEUMATIC DISEASES

Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis

(2009) N. M. Wulffraat et al.   AUTOIMMUNITY

Macrophage activation syndrome: Serological markers and treatment with anti-thymocyte globulin

(2009) Andreea Coca et al.   CLINICAL IMMUNOLOGY

Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states

(2009) Claudia Macaubas et al.   CLINICAL IMMUNOLOGY

Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000–2007)

(2009) Mario Abinun et al.   MOLECULAR IMMUNOLOGY

Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report

(2009) M. Kasher-Meron et al.   RHEUMATOLOGY

Thalidomide: Mechanisms of Action

(2008) Taraneh Paravar et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

(2008) Nicolino Ruperto et al.   LANCET

Amyloidosis—Recent Developments

(2008) Tom Pettersson et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM